Serum β2-microglobulin in patients with bronchial carcinoma and controls

Hällgren, Roger; E, Nõu; Lundqvist, G.

doi:10.1002/1097-0142(19800215)45:4<780::aid-cncr2820450428>3.0.co;2-h

Cited by 18 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The basic data relating to these three tumour types are shown in Table 11. The awareness that serum creatinine levels can influence 02-m levels is appreciated by all investigators, but the age-dependent rise of 02-m, and its tendency to rise more steeply in the elderly [38] are taken into account only by some investigators.…”

Section: Variations Of Serum 02-m I N Adenocarcinomamentioning

confidence: 98%

“…Shuster et al [29], using a serum 02-m of 3 mg/liter as a cut-off, found 33% of patients with lung malignancies to be above this level. In a study of 460 patients suspected of having lung cancer, Hallgren et a1 [38] observed that 21% of 230 patients with lung cancer had a serum 02-m > 3 mg/liter; 11 % of patients with various nonmalignant conditions of the lungs also had serum 02-m > 3 mg/liter. There did not appear to be any significant difference between the different types of lung cancer.…”

Section: Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Beta‐2‐microglobulin review: Its relevance in clinical oncology

Cooper

Plesner²

1980

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Beta-2-microglobulin (beta 2-m) is an intrinsic part of the HLA system and is most probably involved in cell recognition. The levels of free beta 2-m in the blood and urine are influenced by beta 2-m production and its clearance and destruction in the kidney. Many tumors can be associated with an elevated serum beta 2-m, the reason is unknown. The most promising application of beta 2-m as a tumor marker would appear to be lymphoid malignancies, especially multiple myeloma and chronic lymphocytic leukemia.

show abstract

Section: Variations Of Serum 02-m I N Adenocarcinomamentioning

confidence: 98%

Section: Lung Cancermentioning

confidence: 99%

Beta‐2‐microglobulin review: Its relevance in clinical oncology

Cooper

Plesner²

1980

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

“…Multiple lines of evidence show that β2-m is involved in cancer and other human malignancies. Increased synthesis and release of β2-m, as indicated by elevated serum, plasma, or urine β2-m concentration, occurs in several malignant diseases, including prostate cancer, lung cancer, breast cancer, renal cell carcinoma (RCC), gastrointestinal and nasopharyngeal cancers, hepatocellular carcinoma, ovarian cancer, multiple myeloma, and lymphocytic malignancies such as non-Hodgkin’s lymphoma, in addition to autoimmune and chronic infectious diseases [19, 21-29, 49, 50]. Furthermore, a number of studies have demonstrated that the level of serum β2-m is one of the most important independent prognostic factors and survival predictors for some tumors including RCC, multiple myeloma, and T-cell leukemia [22, 24, 28].…”

Section: β2-m As a Biomarker For Cancersmentioning

confidence: 99%

β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy

Nomura¹,

Huang²,

Zhau³

et al. 2014

ACAMC

View full text Add to dashboard Cite

β2-microglobulin (β2-m) has become the focus of intense scrutiny since the discovery of its undesirable roles promoting osteomimicry and cancer progression. β2-m is a well-known housekeeping protein that forms complexes with the heavy chain of major histocompatibility complex class I molecules, which are heterodimeric cell surface proteins that present antigenic peptides to cytotoxic T cells. On recognition of foreign peptide antigens on cell surfaces, T cells actively bind and lyse antigen-presenting cancer cells. In addition to its roles in tumor immunity, β2-m has two different functions in cancer cells, either tumor promoting or tumor suppressing, in cancer cell context-dependent manner. Our studies have demonstrated that β2-m is involved extensively in the functional regulation of growth, survival, apoptosis, and even metastasis of cancer cells. We found that β2-m is a soluble growth factor and a pleiotropic signaling molecule which interacts with its receptor, hemochromatosis protein, to modulate epithelial-to-mesenchymal transition (EMT) through iron-responsive pathways. Specific antibodies against β2-m have remarkable tumoricidal activity in cancer, through β2-m action on iron flux, alterations of intracellular reactive oxygen species, DNA damage and repair enzyme activities, β-catenin activation and cadherin switching, and tumor responsiveness to hypoxia. These novel functions of β2-m and β2-m signaling may be common to several solid tumors including human lung, breast, renal, and prostate cancers. Our experimental results could lead to the development of a novel class of antibody-based pharmaceutical agents for cancer growth control. In this review, we briefly summarize the recent data regarding β2-m as a promising new cancer therapeutic target and discuss antagonizing this therapeutic target with antibody therapy for the treatment of localized and disseminated cancers.

show abstract

“…In humans, also known as component of the cells associated with the heavy chains of major histocompatibility complex (MHC) class I molecules, the β 2 -microglobulin polypeptide is encoded by the B2M gene [1,2]. β2M levels are elevated in many tumors, including small cell lung cancer, T cell leukemia, breast cancer, renal cell carcinoma (RCC), prostate cancer, gastrointestinal cancers, hepatocellular carcinoma, ovarian cancer, multiple myeloma, and lymphocytic malignancies such as non-Hodgkin's lymphoma [3][4][5][6][7][8][9][10][11]. It also associated with an enhanced rate of cell production or disruption, viral infections such as cytomegalovirus (CMV), and some conditions that activate the immune system, such as autoimmune disorders and inflammatory conditions.…”

Section: Introductionmentioning

confidence: 99%